146 related articles for article (PubMed ID: 34634528)
1. Development and validation of an HPLC-MS/MS method for the quantification of the anti-leishmanial drug miltefosine in human skin tissue.
Roseboom IC; Thijssen B; Rosing H; Alves F; Mondal D; Teunissen MBM; Beijnen JH; Dorlo TPC
J Pharm Biomed Anal; 2022 Jan; 207():114402. PubMed ID: 34634528
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of an ultra-high performance liquid chromatography coupled to tandem mass spectrometry method for the quantification of the antileishmanial drug paromomycin in human skin tissue.
Roseboom IC; Thijssen B; Rosing H; Alves F; Younis BM; Musa AM; Beijnen JH; Dorlo TPC
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Nov; 1211():123494. PubMed ID: 36219923
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a high-performance liquid chromatography tandem mass spectrometry method for the quantification of the antiparasitic and antifungal drug amphotericin B in human skin tissue.
Roseboom IC; Thijssen B; Rosing H; Alves F; Sundar S; Beijnen JH; Dorlo TPC
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Aug; 1206():123354. PubMed ID: 35810536
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry.
Dorlo TP; Hillebrand MJ; Rosing H; Eggelte TA; de Vries PJ; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Apr; 865(1-2):55-62. PubMed ID: 18325856
[TBL] [Abstract][Full Text] [Related]
5. Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry.
Kip AE; Rosing H; Hillebrand MJ; Castro MM; Gomez MA; Schellens JH; Beijnen JH; Dorlo TP
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Aug; 998-999():57-62. PubMed ID: 26160472
[TBL] [Abstract][Full Text] [Related]
6. Dermal microdialysis: A method to determine drug levels in the skin of patients with Post kala-azar dermal leishmaniasis (PKDL).
Wijnant GJ; Moulik S; Chatterjee K; Das NK; de la Flor R; Van Bocxlaer K; Croft SL; Chatterjee M
Exp Parasitol; 2024 Feb; 257():108687. PubMed ID: 38114040
[TBL] [Abstract][Full Text] [Related]
7. Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection.
Kip AE; Rosing H; Hillebrand MJ; Blesson S; Mengesha B; Diro E; Hailu A; Schellens JH; Beijnen JH; Dorlo TP
Antimicrob Agents Chemother; 2016 Apr; 60(4):2081-9. PubMed ID: 26787691
[TBL] [Abstract][Full Text] [Related]
8. Highly sensitive UPLC-MS/MS method for the quantification of paromomycin in human plasma.
Roseboom IC; Thijssen B; Rosing H; Mbui J; Beijnen JH; Dorlo TPC
J Pharm Biomed Anal; 2020 Jun; 185():113245. PubMed ID: 32199328
[TBL] [Abstract][Full Text] [Related]
9. LC-coupled ESI MS for quantification of miltefosine in human and hamster plasma.
Jaiswal S; Sharma A; Shukla M; Lal J
Bioanalysis; 2016 Mar; 8(6):533-45. PubMed ID: 26915470
[TBL] [Abstract][Full Text] [Related]
10. Severe post-kala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient.
Abongomera C; Battaglioli T; Adera C; Ritmeijer K
Int J Infect Dis; 2019 Apr; 81():221-224. PubMed ID: 30790722
[TBL] [Abstract][Full Text] [Related]
11. A randomized, open-label study to evaluate the efficacy and safety of liposomal amphotericin B (AmBisome) versus miltefosine in patients with post-kala-azar dermal leishmaniasis.
Pandey K; Pal B; Siddiqui NA; Lal CS; Ali V; Bimal S; Kumar A; Verma N; Das VNR; Singh SK; Topno RK; Das P
Indian J Dermatol Venereol Leprol; 2021; 87(1):34-41. PubMed ID: 33580944
[TBL] [Abstract][Full Text] [Related]
12. Post-kala-azar dermal leishmaniasis with mucosal involvement: an unusual case presentation including successful treatment with miltefosine.
Salam MA; Siddiqui MA; Nabi SG; Bhaskar KR; Mondal D
J Health Popul Nutr; 2013 Jun; 31(2):294-7. PubMed ID: 23930349
[TBL] [Abstract][Full Text] [Related]
13. Acute uveitis: A rare adverse effect of miltefosine in the treatment of post-kala-azar dermal leishmaniasis.
Pandey K; Pal B; Topno RK; Lal CS; Das VNR; Das P
Rev Soc Bras Med Trop; 2020; 54():e20200208. PubMed ID: 33338118
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and bioavailability assessment of Miltefosine in rats using high performance liquid chromatography tandem mass spectrometry.
Valicherla GR; Tripathi P; Singh SK; Syed AA; Riyazuddin M; Husain A; Javia D; Italiya KS; Mishra PR; Gayen JR
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Sep; 1031():123-130. PubMed ID: 27475453
[TBL] [Abstract][Full Text] [Related]
15. Identification of phospholipid species affected by miltefosine action in Leishmania donovani cultures using LC-ELSD, LC-ESI/MS, and multivariate data analysis.
Imbert L; Ramos RG; Libong D; Abreu S; Loiseau PM; Chaminade P
Anal Bioanal Chem; 2012 Jan; 402(3):1169-82. PubMed ID: 22065347
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.
Dorlo TP; van Thiel PP; Huitema AD; Keizer RJ; de Vries HJ; Beijnen JH; de Vries PJ
Antimicrob Agents Chemother; 2008 Aug; 52(8):2855-60. PubMed ID: 18519729
[TBL] [Abstract][Full Text] [Related]
17. Anti-leishmanial activity of a topical miltefosine gel in experimental models of New World cutaneous leishmaniasis.
Neira LF; Mantilla JC; Escobar P
J Antimicrob Chemother; 2019 Jun; 74(6):1634-1641. PubMed ID: 30815688
[TBL] [Abstract][Full Text] [Related]
18. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
[TBL] [Abstract][Full Text] [Related]
19. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
[TBL] [Abstract][Full Text] [Related]
20. Miltefosine Induced Reduced Male Fertility Capacity after Treatment of Post Kala-azar Dermal Leishmaniasis, Bangladesh.
Basher A; Rashid MM; Habibullah AM; Nath R; Akter D; Chowdhury IH; Azim A; Nath P; Faiz MA
Mymensingh Med J; 2019 Apr; 28(2):328-332. PubMed ID: 31086147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
